Payment overview · 2025
General Payments
$44.17
2 reported records · 1 companies
Healthcare provider profile · identity verified
Michael A Wilson, MD
Allopathic & Osteopathic Physicians|Family Medicine · YORK, PA · NPI 1003836784
Verified facts
What the public records show
CMS Open Payments records show Michael A Wilson, MD received $44.17 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.17 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $44.17 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.17 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 211 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
211 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 609 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 428 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 404 | 88 |
| Simvastatin | Simvastatin | 402 | 89 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 73 |
| Lisinopril | Lisinopril | 314 | 81 |
| Omeprazole | Omeprazole | 300 | 73 |
| Furosemide | Furosemide | 292 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 54 |
| Eliquis | Apixaban | 211 | 35 |
| Metformin Hcl | Metformin Hcl | 198 | 53 |
| Sertraline Hcl | Sertraline Hcl | 196 | 47 |
| Gabapentin | Gabapentin | 195 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 43 |
| Alprazolam | Alprazolam | 182 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 39 |
| Prednisone | Prednisone | 158 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 35 |
| Meloxicam | Meloxicam | 130 | 36 |
| Potassium Chloride | Potassium Chloride | 123 | 31 |
| Allopurinol | Allopurinol | 119 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 41 |
| Losartan Potassium | Losartan Potassium | 114 | 32 |
| Bupropion Xl | Bupropion Hcl | 112 | 30 |
| Tramadol Hcl | Tramadol Hcl | 111 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 24 |
| Donepezil Hcl | Donepezil Hcl | 110 | 19 |
| Glipizide Er | Glipizide | 104 | 28 |
| Lorazepam | Lorazepam | 96 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 28 |
| Alendronate Sodium | Alendronate Sodium | 79 | 17 |
| Finasteride | Finasteride | 79 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 27 |
| Atenolol | Atenolol | 74 | 18 |
| Carvedilol | Carvedilol | 71 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 19 |
| Spironolactone | Spironolactone | 62 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 17 |
| Glipizide | Glipizide | 57 | 12 |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 32 |
| Famotidine | Famotidine | 48 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 11 |
| Cephalexin | Cephalexin | 46 | 38 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 33 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 11 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 17 |
| Primidone | Primidone | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 24 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 18 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 14 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $44.17 · 2 records | PFIZER INC. | ELIQUIS, NURTEC ODT, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error